Invisible Yet Accountable: How Clinical Supply Pressures Build Strategic Leaders
By Rachel Grabenhofer, Chief Editor, Clinical Supply Leader
Clinical supply professionals don’t face one problem at a time, they face ten — all urgent, all interconnected, and all emerging globally. (I’m preaching to the choir, right?) At the center of this pressure is a persistent truth: they are forecasting and making decisions in environments where assumptions decay faster than plans. The role is defined by continual triage and tradeoffs.
But this article will show how that constant pressure — compounded by operating largely unseen yet fully accountable — doesn’t just shape supply decisions, it systematically develops the kind of judgment, risk tolerance, and decision-making that translate well beyond the function itself.
Supply experts generally maintain the same outlook: the success of a clinical trial depends on supply execution as much as it does on recruiting, timelines, and protocol design. In many organizations, however, supply remains structurally downstream — brought in after key decisions have already been made and expected to execute against constantly shifting assumptions.
Those assumptions may shape planning, but they don’t always hold up in real-world dynamics. As Kevin Coker, innovation strategist and MedTech lead at MD Anderson Cancer Center, emphasized, “Clinical trials are now being executed in an environment where predictability can no longer be assumed.”
This misalignment creates a persistent operating model defined by tension: scarcity vs. waste, speed vs. control, and increasingly, human judgment vs. algorithmic forecasts.
Furthermore, in many cases, the root cause sits upstream of supply entirely. Industry advisor Tom Walls, principal and founder of Axion Bridge Consulting, explained: “Clinical supply shortages are often attributed to manufacturing yield, capacity, or distribution execution. In reality, many of these issues originate much earlier — embedded in enrollment assumptions that go unchallenged.”
So, despite advances in technologies like IRT/RTSM and AI-enabled forecasting, many of the core challenges in clinical supply remain unchanged. Forecasts are still wrong. Drug is still constrained. And decision-making often happens with incomplete information and little margin for error. That’s what Staci Hargraves sees, as she explained in a recent interview.
A caveat: Hargraves emphasizes it’s been nearly a decade since she was in clinical supply – but as you’ll see, those lessons never left her. Her past roles included: manager of
investigational materials (Otsuka America Pharmaceutical, Inc.), senior manager of U.S. clinical supply services (UCB Pharma), and senior director of clinical operations (Regeneron Pharmaceuticals, Inc.), among others.
More recently, she’s been focused on operations, patient solutions, portfolio delivery, and innovative health, engagement and advocacy positions (J&J Innovative Medicine) in management and director roles, and she serves as a transformation executive.
In this discussion, Hargraves articulates what many leaders in the field experience but rarely see acknowledged: that clinical supply is not just operational complexity. It’s a high-stakes environment where risk, decision-making, and accountability converge in real time. Hargrave’s perspective reinforces a central truth for today’s clinical supply teams: technology may be evolving, but outcomes still depend on how leaders interpret risk, trust data, and act under uncertainty.
Clinical Supply as the Overlooked Engine
For Hargraves, the disconnect between clinical supply’s strategic importance and how it is treated within organizations is immediate and persistent. “I always tell people — even in my executive roles — that the clinical supply function and capability is the most overlooked in terms of what we do.”
While today she holds an executive vantage point, with a more macro-level view of clinical supply and challenges tied to filings, QA, QC, and data, that distance hasn’t diminished how she talks about the clinical supply function. If anything, it’s reinforced it.
“I still tell people that the clinical supplies experience was the best on-the-job MBA you could ever imagine.”
Leadership Forged in Constant Uncertainty
In Hargraves’ words, that “MBA” is built not in theory, but in repetition — navigating uncertainty over and over again. “You’re dealing with so many unknowns all the time: moving supplies through customs, managing things that are lost or expired…” That environment — high stakes, limited visibility, and constant recalibration — is what ultimately forges clinical supply leaders.
Clinical supply sits at the intersection of regulations, logistics, and operational complexity, forcing professionals to engage across disciplines simultaneously. “You get this unbelievable level of regulatory, legal, and problem-solving experience.”
Over time, the accumulation of those decisions builds something more valuable than technical expertise: leadership judgment.
“It ingrained in me how to problem-solve as a leader — how to look at the macro level and decide what problems to tackle, because in clinical supply, you’ve got 10 problems every single day coming at you,” Hargraves says.
In the Trenches: Clinical vs. Commercial Supply
That environment stands in sharp contrast to commercial supply chains, which are often more structured and predictable. “I think sometimes commercial supply gets all the glory and clinical supply is in the trenches — but there would be no commercial supply if clinical hadn’t come first,” Hargrave says.
Clinical operates earlier in the lifecycle — before revenue, before certainty, and often before systems are fully defined. “The expense is on the clinical side before you're even generating revenue… it’s all about recruitment, retention … and how fast we can recruit.”
At the same time, supply must balance competing pressures like cost control, availability, and risk mitigation, often with limited visibility. “So we want to be careful in forecasting — but we also want to react when there's not enough.”
Unlike commercial, where supply chains are largely mapped and stable, clinical remains fluid. “You know the supply chain. You know what the import-export looks like… we know none of that on the clinical side — it’s trial and error.”
The Visibility Paradox
If clinical supply is so central, why is it often treated as peripheral? For Hargraves, the answer lies in when and whether the function is included in early discussions. “That’s the problem. Clinical supply should be at the planning conversation.”
Because the underlying reality is straightforward: “Without supply, there is no site — and there is no patient.”
That dependency is recognized directly by clinical leadership. Isabel Luther, executive consultant at Biotech Bay Consulting, highlighted, “Clinical operations really cannot achieve programmatic goals without strong partnerships with supply teams… Even if clinical operations carries ultimate accountability, the expertise and management from clinical supply teams are critical for success.”
And yet supply is frequently expected to operate invisibly; until something goes wrong.
Clinical supply operates in a paradox: expected to be invisible when it works, but fully accountable when visibility increases.
Hargraves continues: “They want clinical supply to be invisible. It’s an unsung hero… until it isn’t.” When issues surface, visibility increases — along with accountability, but not authority. “Then you get all the heat when something goes wrong, but no one says thank you when you’ve actually filed.”
It’s this dynamic — high accountability without consistent visibility — that drives leadership development in the function. But it also prompts a critical question: what type of individual not only survives these pressures, but is shaped by them? That’s where the story of clinical supply leadership really begins – in Part 2 of this discussion.
Staci Hargraves is an accomplished executive with experience implementing large and AI-derived transformation, enterprise operations, and patient-focused strategies across the pharmaceutical, biotech, clinical, and health-tech sectors. Most recently, she served as SVP/Head of Transformation, demonstrating expertise in enterprise transformation & modernization (R&D, Commercial, Corporate Affairs, Clinical Ops, G&A); operational leadership with P&L, portfolio, and cross-functional accountability; program office & strategic execution for multi-year initiatives; and patient impact, advocacy & equity strategies.
Additional areas of expertise include: executive communications, culture shaping & change leadership; building high-performing global teams across matrixed environments; and AI-enabled operational redesign and workflow optimization. A purpose-driven leader, Hargraves is known for reshaping global operations, defining strategic vision, and translating it into actionable goals while fostering a more efficient, inclusive environment.